A Johns Hopkins study of 52 people living with HIV has uncovered reassuring news for those whose blood still shows detectable traces of the virus despite years of strict treatment: most of what doctors find isn't actually infectious. The research, published in Nature Communications, reveals that approximately 95% of detectable viral traces in these cases are defective, non-infectious copies of HIV—a finding that could ease the anxiety of thousands who fear their treatment is failing.
Understanding why this matters requires knowing how modern HIV treatment works. Since 1996, antiretroviral drugs have been transformative, allowing most people with HIV to live long, healthy lives by preventing the virus from infecting new immune cells. Yet these medications cannot retroactively stop cells that were already infected from releasing viral particles into the bloodstream. In the vast majority of cases, this means patients can achieve undetectable viral loads. But in less than 1% of people—those with what's called non-suppressible viremia—traces of HIV persist in the blood even with perfect medication adherence and no symptoms.
For years, these persistent traces have caused considerable worry. People with HIV are taught that an undetectable viral load is the absolute goal, and discovering detectable virus months or years into treatment can trigger fears of viral rebound or the possibility of transmitting the virus to sexual partners.
Dr. Francesco R. Simonetti, senior author of the study and an assistant professor of medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine, led the team that examined blood samples from 52 people with detectable HIV despite long-term antiretroviral therapy. Samples were collected between 2021 and 2025 from participants in the U.S., Canada, and Denmark. The majority were white men between ages 58 and 68. The researchers discovered something striking: the vast majority of detectable virus was rendered harmless by specific genetic defects. Most of these defects—mutations or deletions—occurred in a crucial region of HIV's genetic material called the 5'-leader, which normally orchestrates the virus's ability to reproduce. When this region is damaged, the virus cannot generate infectious copies.
"From a clinical perspective, this is important because people with HIV are taught that the absolute goal of their medication is to achieve undetectable viral load and they worry," Simonetti explained. The new findings should provide relief to many living with HIV who have experienced the fear of detectable virus despite diligent treatment.
The implications extend far beyond peace of mind. If clinicians can confirm that detectable virus consists only of defective copies released from a small number of infected cells, they may be able to eliminate the need for additional medications and prevent related complications. The test the researchers developed is cost-effective and can be used broadly in HIV clinics and research settings. For people with HIV seeking access to surgeries, transplants, or clinical trial participation, confirmation that their virus is truly under control could be life-changing. The study demonstrates that not all detectable virus is created equal—and sometimes, what appears to be a treatment failure is simply a harmless echo of past infection.